Metabolic research

SELECT: cardiovascular outcomes in a specific high-risk population

SELECT studied cardiovascular events, rather than weight change alone.

Clinical trialPaper year: 2023Semaglutide

01 / DESIGN

What was studied?

This randomized trial enrolled 17,604 adults aged at least 45 with established cardiovascular disease and overweight or obesity, but no history of diabetes.

02 / FINDINGS

What did the researchers report?

The composite cardiovascular endpoint occurred in 6.5% of the semaglutide group and 8.0% of the placebo group during follow-up. Adverse events leading to permanent treatment discontinuation were more frequent with semaglutide.

03 / INTERPRETATION

What are the limits?

These findings concern secondary prevention in an already high-risk population. They should not be generalized to healthy people, all cardiovascular conditions or untested research materials.

Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.

RESEARCH CONTEXT

These are original reading notes on published studies, not product testimonials. Clinical studies used their own pharmaceutical formulations and protocols; their findings do not establish the safety, efficacy or equivalence of materials in our catalog. No personal-use or treatment guidance is provided.

What was studied?

What did the researchers report?

What are the limits?

Continue reading.